CTOs on the Move

TrialAssure

www.trialassure.com

 
TrialAssure – the technology arm of MMS Holdings – is an award-winning, global clinical trial disclosure and transparency reporting suite with unmatched experience in helping clients navigate complex regulatory submission and reporting challenges. TrialAssure helps meet regulatory compliance goals through a flexible, scalable, and streamlined platform that regularly adapts to ever-changing clinical trial disclosure requirements. Established in 2009, the TrialAssure suite was built from the ground up as a single, integrated transparency system, and it is continually strengthened by the experience of leading pharmaceutical industry compliance experts.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Mohamad Zahreddine
Chief Information Officer and Chief Technology Officer Profile

Similar Companies

Success TMS

Get relief from depression in under 8 weeks. Safe & FDA approved. Covered by Insurance & Medicare. Get your FREE consultation. Book an appointment Today!

Family Guidance Centers

Since 1980, we have been offering our clients experienced and compassionate clinical care, which gives us the distinction of having served the people of Chesterfield longer than any other private mental health group practice in the county. Our staff of...

Sanford House

Sanford House in Grand Rapids, Michigan is a drug and alcohol rehab and recovery center. We offer residential and non-residential treatment options for both men and women in Michigan and across the country. Our Johns Street location provides detox for ...

Camber Pharmaceuticals Inc

Camber Pharmaceuticals Inc is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Edgewise Therapeutics

Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it`s Series B financing round which will support the advancement of Edgewise Therapeutic`s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company`s pipeline. The company`s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.